151 related articles for article (PubMed ID: 23148675)
1. Positron emission tomography in malignancies of the liver, pancreas and biliary tract - indications and potential pitfalls.
Ansari D; Keussen I; Andersson R
Scand J Gastroenterol; 2013 Mar; 48(3):259-65. PubMed ID: 23148675
[TBL] [Abstract][Full Text] [Related]
2. Clinical applications of (18)F-FDG PET in the management of hepatobiliary and pancreatic tumors.
De Gaetano AM; Rufini V; Castaldi P; Gatto AM; Filograna L; Giordano A; Bonomo L
Abdom Imaging; 2012 Dec; 37(6):983-1003. PubMed ID: 22527152
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of (18)F-fluorodeoxyglucose positron-emission tomography for preoperative evaluation of biliary tract cancer.
Yamada I; Ajiki T; Ueno K; Sawa H; Otsubo I; Yoshida Y; Shinzeki M; Toyama H; Matsumoto I; Fukumoto T; Nakao A; Kotani J; Ku Y
Anticancer Res; 2012 Nov; 32(11):5105-10. PubMed ID: 23155288
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic and hepatobiliary cancers.
Buck AK; Herrmann K; Eckel F; Beer AJ
Methods Mol Biol; 2011; 727():243-64. PubMed ID: 21331938
[TBL] [Abstract][Full Text] [Related]
5. [18F]Fluorodeoxyglucose PET/Computed Tomography in Gastrointestinal Malignancies.
Donswijk ML; Hess S; Mulders T; Lam MG
PET Clin; 2014 Oct; 9(4):421-41, v-vi. PubMed ID: 26050945
[TBL] [Abstract][Full Text] [Related]
6. Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours.
Yao J; Gan G; Farlow D; Laurence JM; Hollands M; Richardson A; Pleass HC; Lam VW
ANZ J Surg; 2012 Mar; 82(3):140-4. PubMed ID: 22510123
[TBL] [Abstract][Full Text] [Related]
7. Recurrent pancreatic carcinoma and cholangiocarcinoma: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT).
Cameron K; Golan S; Simpson W; Peti S; Roayaie S; Labow D; Kostakoglu L
Abdom Imaging; 2011 Aug; 36(4):463-71. PubMed ID: 21465110
[TBL] [Abstract][Full Text] [Related]
8. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
9. Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective study.
Buchs NC; Bühler L; Bucher P; Willi JP; Frossard JL; Roth AD; Addeo P; Rosset A; Terraz S; Becker CD; Ratib O; Morel P
J Gastroenterol Hepatol; 2011 Apr; 26(4):657-62. PubMed ID: 21155879
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography-computed tomography in liver imaging.
Sharma B; Martin A; Zerizer I
Semin Ultrasound CT MR; 2013 Feb; 34(1):66-80. PubMed ID: 23395319
[TBL] [Abstract][Full Text] [Related]
11. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
[TBL] [Abstract][Full Text] [Related]
12. [18F]Fluorodeoxyglucose PET for Interventional Oncology in Liver Malignancy.
Samim M; El-Haddad GE; Molenaar IQ; Prevoo W; van den Bosch MA; Alavi A; Lam MG
PET Clin; 2014 Oct; 9(4):469-95, vi. PubMed ID: 26050948
[TBL] [Abstract][Full Text] [Related]
13. FDG-PET/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy.
De Iaco P; Musto A; Orazi L; Zamagni C; Rosati M; Allegri V; Cacciari N; Al-Nahhas A; Rubello D; Venturoli S; Fanti S
Eur J Radiol; 2011 Nov; 80(2):e98-103. PubMed ID: 20688446
[TBL] [Abstract][Full Text] [Related]
14. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
15. Image-guided Treatment in the Hepatobiliary System: Role of Imaging in Treatment Planning and Posttreatment Evaluation.
Bajpai S; Kambadakone A; Guimaraes AR; Arellano RS; Gervais DA; Sahani D
Radiographics; 2015; 35(5):1393-418. PubMed ID: 26252365
[TBL] [Abstract][Full Text] [Related]
16. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
17. False-positive uptake on 2-[¹⁸F]-fluoro-2-deoxy-D-glucose (FDG) positron-emission tomography/computed tomography (PET/CT) in oncological imaging.
Culverwell AD; Scarsbrook AF; Chowdhury FU
Clin Radiol; 2011 Apr; 66(4):366-82. PubMed ID: 21356398
[TBL] [Abstract][Full Text] [Related]
18. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis and management of pancreatic cancer; comparison with multidetector row computed tomography, magnetic resonance imaging and endoscopic ultrasonography.
Ergul N; Gundogan C; Tozlu M; Toprak H; Kadıoglu H; Aydin M; Cermik TF
Rev Esp Med Nucl Imagen Mol; 2014; 33(3):159-64. PubMed ID: 24140024
[TBL] [Abstract][Full Text] [Related]
19. F-18 FDG PET/CT scan in biliary cystadenocarcinoma.
Takanami K; Kaneta T; Yamada S; Takahashi S
Clin Nucl Med; 2009 Jul; 34(7):470-2. PubMed ID: 19542961
[No Abstract] [Full Text] [Related]
20. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
